

**REMARKS**

Entry of the amendments above and favorable consideration of this application are respectfully requested in view of the comments below.

The specification has been amended to include related U.S. application data. The original claims are canceled herein and are replaced with new claims 24 through 38. Accordingly, claims 24-38 are presented for examination on the merits.

New claims 24-28 are directed to the named compounds in the specification. Support for new claims 24-28 is found in the specification, e.g. on page 6 and in the Tables.


New claims 29, 31, 33, 35 and 37 are directed to a therapeutic composition of a named compound. Support for each of new claim 29, 31, 33, 35 and 37 is found for example, on pages 7-8 of the specification. Support for claims 30, 32, 34, 36 and 38, which are directed to methods of treating ocular hypertension or glaucoma by administration of the claimed compounds, is found, for example, on page 7, lines 20-32.

**Conclusion**

Applicants believe all claims are in condition for allowance. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,



Joseph F. Reidy  
Attorney For Applicants  
Registration No. 39,340

Date: 11/25/2003  
Pharmacia Aktiebolag/ a Pfizer company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-7320  
Fax: (858) 678-8233